Overall, for affected individuals, most (>85%) respondents were comfortable returning clinically relevant pathogenic variants in PD genes and >70% were comfortable returning the results on GBA1 variants or pathogenic variants in other neurologic disorder-related genes. This evidence concerns the gene GBA1 and nervous system disorder.